kabutan

KAKEN PHARMA, Ordinary Profit Forecast for the Fiscal Year Revised Downward by 53%

Fri Sep 26, 2025 4:00 pm JST Revision

4521 KAKEN PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Guidance Update Report

KAKEN PHARMACEUTICAL CO.,LTD. <4521> [TSE Prime] announced a performance revision after the market closed on September 26th (16:00). The consolidated ordinary profit forecast for the fiscal year ending March 2026 has decreased 53.3%, from the previous forecast of 6.00 billion yen to 2.80 billion yen (compared to 21.2 billion yen in the previous period), leading to an increase in the profit decline rate from 71.8% to 86.8%.

Furthermore, The company continued to decline to disclose its earnings forecast for April to September (first half).

Kabutan News

Guidance Update

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2026 Prev 88,000 5,200 6,000 3,400 89.8 190 May 12, 2025 J-GAAP
Mar, 2026 New 86,300 2,100 2,800 2,300 60.7 190 Sep 26, 2025 J-GAAP
Revision Rate -1.9% -59.6% -53.3% -32.4% -32.3%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 51,372 19,579 19,823 14,286 377.2 115 Nov 8, 2024 J-GAAP
Apr - Sep, 2025 Guidance ー ー ー ー － 95 May 12, 2025 J-GAAP
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 72,044 9,513 9,951 8,025 212.7 150 May 14, 2024 J-GAAP
Mar, 2025 94,035 21,034 21,279 13,945 365.4 190 May 12, 2025 J-GAAP
Mar, 2026 Guidance 86,300 2,100 2,800 2,300 60.7 190 Sep 26, 2025 J-GAAP
YoY -8.2% -90.0% -86.8% -83.5% -83.4%

Related Articles